Effects of coenzyme Q10 supplementation on lipid profiles and liver enzymes of nonalcoholic fatty liver disease (NAFLD) patients: A systematic review and meta‐analysis of randomized controlled trials

As an antioxidant, coenzyme Q 10 (CoQ10) has been proposed as a possible treatment for non‐alcoholic fatty liver disease (NAFLD). In the present meta‐analysis, we aimed to determine the effects of CoQ10 supplementation on lipid profiles and liver enzymes of NAFLD patients. We searched PubMed, Web of Science, Scopus, and Cochrane Library on 21 April 2022 to retrieve randomized controlled trials on NAFLD patients in which CoQ10 was utilized as a treatment. Data were pooled using the random‐effects model and weighted mean difference (WMD) was considered as the summary effect size. The analysis of the six included studies indicated an overall non‐significant decrease in the lipid profiles (total cholesterol (TC), low‐density lipoprotein cholesterol (LDL), high‐density lipoprotein cholesterol (HDL), and triglyceride (TG)), and liver enzymes (aspartate transaminase (AST), alanine transaminase (ALT), and gamma‐glutamyltransferase (GGT)) of NAFLD patients who received CoQ10. Sensitivity analysis using “leave‐one out” method showed a significant reduction in AST, and GGT after excluding certain studies. Also, subgroup analyses showed significant difference based on CoQ10 dose for TC, AST, and GGT, and also a significant decrease in AST based on the duration of the intervention. No publication bias was found between the studies. Although an overall non‐significant decrease was observed in lipid profiles and liver enzymes of NAFLD patients, the results of sensitivity and subgroup analyses showed significant effects of CoQ10 in certain conditions. Further RCTs should be done in light of our findings.